Advertisement

La radiologia medica

, Volume 123, Issue 6, pp 469–473 | Cite as

Dentate nucleus T1 hyperintensity: is it always gadolinium all that glitters?

  • Luca PasquiniEmail author
  • Maria Camilla Rossi Espagnet
  • Antonio Napolitano
  • Daniela Longo
  • Alice Bertaina
  • Emiliano Visconti
  • Paolo Tomà
SHORT COMMUNICATION

Abstract

In the last few years, several scientific papers and reports have demonstrated magnetic resonance (MR) signal intensity (SI) changes on pre-contrast T1-weighted images following multiple gadolinium-based contrast agents (GBCA) administrations, particularly following the exposure to linear GBCAs. Pathological animal and human post-mortem studies have confirmed the relationship between this radiological finding and the presence of gadolinium accumulation in vulnerable brain regions in patients with normal renal function. In this short communication, we report the case of a 15-year-old patient affected by b-cell acute lymphoblastic leukemia (bALL) who developed a hyperintense signal in the dentate nuclei following multiple administrations of a macrocyclic GBCA. The purpose of this report is to discuss possible differential diagnoses of this radiological finding with special focus on the differentiation between iron or manganese accumulation, post-irradiation changes and GBCA-related Gd deposition, highlighting the importance of the acquisition of accurate clinical data to improve our scientific knowledge.

Keywords

GBCA Gadolinium Dentate Nucleus MRI Macrocyclic 

Notes

Compliance with ethical standards

Conflict of interest

Author L.P declares that he has no conflict of interest. Author M.C.R.E. declares that she has no conflict of interest. Author A.N. declares that he has no conflict of interest. Author D.L. declares that she has no conflict of interest. Author A.B. declares that she has no conflict of interest. Author E.V. declares that he has no conflict of interest. Author P.T. declares that he has no conflict of interest.

Ethical approval

This article does not contain any studies with animals performed by any of the authors. Due to the typology of the report, the ethical approval was considered unnecessary.

Informed consent

Informed consent was obtained from all individual participants (or next of kin) included in the study.

References

  1. 1.
    Radbruch A, Weberling LD, Kieslich PJ et al (2015) Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 275:783–791CrossRefPubMedGoogle Scholar
  2. 2.
    Kanda T, Osawa M, Oba H et al (2015) High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 275:803–809CrossRefPubMedGoogle Scholar
  3. 3.
    Cao Y, Huang DQ, Shih G, Prince MR (2016) Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol 206:414–419CrossRefPubMedGoogle Scholar
  4. 4.
    Radbruch A, Weberling LD, Kieslich PJ et al (2016) Intraindividual analysis of signal intensity changes in the dentate nucleus after consecutive serial applications of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 51:683–690CrossRefPubMedGoogle Scholar
  5. 5.
    Radbruch A (2016) Are some agents less likely to deposit gadolinium in the brain? Magn Reson Imaging 34:1351–1354CrossRefPubMedGoogle Scholar
  6. 6.
    Lohrke J, Frisk AL, Frenzel T et al (2017) Histology and gadolinium distribution in the rodent brain after the administration of cumulative high doses of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 52:324–333CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Frenzel T, Apte C, Jost G, Schöckel L, Lohrke J, Pietsch H (2017) Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats. Invest Radiol 52:396–404.  https://doi.org/10.1097/rli.0000000000000352. [Epub ahead of print]
  8. 8.
    McDonald RJ, McDonald JS, Kallmes DF et al (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275:772–782CrossRefPubMedGoogle Scholar
  9. 9.
    McDonald RJ, McDonald JS, Kallmes DF et al (2017) Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology 27:161595.  https://doi.org/10.1148/radiol.2017161595. [Epub ahead of print]
  10. 10.
    Rossi Espagnet MC, Bernardi B, Pasquini L, Figà-Talamanca L, Tomà P, Napolitano A (2017) Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children. Pediatr Radiol.  https://doi.org/10.1007/s00247-017-3874-38 CrossRefPubMedGoogle Scholar
  11. 11.
    Roberts D, Welsh C, LeBel D, Davis W (2017) Distribution map of gadolinium deposition within the cerebellum following GBCA administration. Neurology 88:1206–1208.  https://doi.org/10.1212/wnl.0000000000003735 CrossRefPubMedGoogle Scholar
  12. 12.
    Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann H (2008) Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol 43:817–828CrossRefPubMedGoogle Scholar
  13. 13.
    Prybylski J, Semelka R, Jay M (2017) The stability of gadolinium-based contrast agents in human serum: a reanalysis of literature data and association with clinical outcomes. Magn Reson Imaging 38:145–151.  https://doi.org/10.1016/j.mri.2017.01.006 CrossRefPubMedGoogle Scholar
  14. 14.
    Murata N, Gonzalez-Cuyar LF, Murata K et al (2016) Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol 51:447–453CrossRefPubMedGoogle Scholar
  15. 15.
    Wnorowski M, Prosch H, Prayer D, Janssen G, Gadner H, Grois N (2008) Pattern and course of neurodegeneration in langerhans cell histiocytosis. J Pediatr 153:127–132.  https://doi.org/10.1016/j.jpeds.2007.12.042 CrossRefPubMedGoogle Scholar
  16. 16.
    Bond K, Brinjikji W, Eckel L, Kallmes D, McDonald R, Carr C (2017) Dentate update: imaging features of entities that affect the dentate nucleus. AJNR Am J Neuroradiol.  https://doi.org/10.3174/ajnr.a5138 CrossRefPubMedGoogle Scholar
  17. 17.
    Kasahara S, Miki Y, Kanagaki M et al (2011) Hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with a history of brain irradiation. Radiology 258:222–228CrossRefPubMedGoogle Scholar
  18. 18.
    Adin ME, Kleinberg L, Vaidya D et al (2015) Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. AJNR Am J Neuroradiol 36:1859–1865CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Rossi Espagnet M, Pasquini L, Napolitano A et al (2016) Magnetic resonance imaging patterns of treatment-related toxicity in the pediatric brain: an update and review of the literature. Pediatr Radiol 47:633–648.  https://doi.org/10.1007/s00247-016-3750-4 CrossRefPubMedGoogle Scholar
  20. 20.
    Qiu D, Chan GC, Chu J et al (2014) MR quantitative susceptibility imaging for the evaluation of iron loading in the brains of patients with β-thalassemia major. AJNR Am J Neuroradiol 35:1085–1090CrossRefPubMedGoogle Scholar
  21. 21.
    Maximova N, Gregori M, Zennaro F, Sonzogni A, Simeone R, Zanon D (2016) Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients. Radiology 281:418–426CrossRefPubMedGoogle Scholar
  22. 22.
  23. 23.
    American College of Radiology (ACR) response to European PRAC recommendation. Available at: https://www.acr.org/About-Us/Media-Center/Press-Releases/2017-Press-Releases/20170404-ACR-Response-to-the-European-PRAC-Recommendations. Accessed 29 March 2017
  24. 24.
    U.S. Food & Drug Administration (FDA) statement on brain Gd retention. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm559007.htm. Accessed 29 March 2017
  25. 25.

Copyright information

© Italian Society of Medical Radiology 2018

Authors and Affiliations

  1. 1.Neuroradiology Unit, Imaging DepartmentBambino Gesù Children’s HospitalRomeItaly
  2. 2.NESMOS Department, Radiology UnitSant’Andrea Hospital, La Sapienza University of RomeRomeItaly
  3. 3.Enterprise Risk Management, Medical Physics DepartmentIRCCS, Bambino Gesù Children’s HospitalRomeItaly
  4. 4.Department of Hematology and OncologyBambino Gesù Children’s HospitalRomeItaly
  5. 5.Neuroradiology UnitM. Bufalini HospitalCesenaItaly
  6. 6.Imaging DepartmentBambino Gesù Children’s HospitalRomeItaly

Personalised recommendations